```html

G6PD‑Related Neonatal Jaundice: A Complete Guide for Parents and Caregivers

Overview

Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency is the most common inherited enzyme deficiency in humans, affecting an estimated 400 million people worldwide. When a newborn with G6PD deficiency develops elevated bilirubin levels, the condition is called **G6PD‑related neonatal jaundice**. The excess bilirubin causes the characteristic yellowing of the skin and eyes (jaundice) and can progress rapidly because the newborn’s liver is immature and the red‑blood‑cell membranes are more fragile without adequate G6PD activity.

The disorder is inherited in an X‑linked recessive pattern, meaning it predominantly affects males, though females can be carriers and, in rare cases, display symptoms. The prevalence varies by ethnicity: up to 10‑15% of males in sub‑Saharan Africa, the Mediterranean, the Middle East, and parts of Southeast Asia are affected, whereas rates in Northern Europe and North America are <1% (World Health Organization, 2021).

Symptoms

Neonatal jaundice caused by G6PD deficiency may appear within the first 24‑48 hours after birth and can be more severe than physiologic jaundice. Below is a complete list of signs to watch for, grouped by system.

Skin and Eyes

• Yellow discoloration of the skin: Starts on the face and progresses to the chest, abdomen, and limbs.
• Yellowing of the sclera (white of the eyes): Often the earliest sign, visible before skin changes become obvious.

Neurologic

• Extreme irritability or lethargy: Bilirubin neurotoxicity can depress the central nervous system.
• Feeding difficulties: Poor latch, reduced sucking, or vomiting.
• High‑pitched cry or loss of cry.
• Seizures or abnormal movements: Late sign of bilirubin‑induced encephalopathy (kernicterus).

General

• Fever or hypothermia: May accompany infection which can precipitate hemolysis.
• Rapid heart rate (tachycardia) or breathing (tachypnea).
• Dark urine: Indicates hemoglobin breakdown products.
• Pale or dark stools: Dark (black) stools can suggest excess bilirubin excretion.

Causes and Risk Factors

G6PD deficiency is caused by mutations in the G6PD gene on the X chromosome. Over 200 variants exist; the most severe (Class I) cause chronic nonspherocytic hemolytic anemia, while the milder (Class II/III) mainly predispose to episodic hemolysis when exposed to triggers.

Primary Causes

• Genetic mutation: Inherited from a mother who is a carrier or affected.
• Oxidative stress in the newborn: The transition from fetal to extra‑uterine life increases oxygen exposure, and the immature liver cannot efficiently conjugate bilirubin.

Risk Factors

• Ethnicity: African, Mediterranean, Middle Eastern, South Asian, and some Latin American populations have higher carrier rates.
• Male sex: Because males have only one X chromosome, a single defective gene results in full deficiency.
• Family history: A brother, maternal uncle, or grandfather with G6PD deficiency or neonatal jaundice.
• Exposure to oxidative triggers during pregnancy or early life: Certain drugs (e.g., sulfonamides, nitrofurantoin), infections, or foods (fava beans) can precipitate hemolysis.
• Prematurity: Preterm infants have reduced G6PD activity and diminished hepatic bilirubin conjugation capacity.

Diagnosis

Early identification is essential to prevent bilirubin‑induced brain injury.

Screening Tests

• Newborn heel‑stick bilirubin measurement: Quantitative transcutaneous or serum total bilirubin (TB) levels are obtained within 24 hours of birth if jaundice is suspected.
• G6PD enzyme assay: Performed on a cord blood sample or heel‑stick. The quantitative spectrophotometric assay measures the rate of NADPH formation; values < 30% of normal indicate deficiency.

Confirmatory Tests

• Molecular genetic testing: DNA analysis can identify specific G6PD mutations, useful for family counseling.
• Complete blood count (CBC) and reticulocyte count: Detect hemolysis (low hemoglobin, elevated reticulocytes).
• Peripheral blood smear: May show bite cells or Heinz bodies characteristic of oxidative damage.

Interpretation of Bilirubin Levels

Clinicians use the American Academy of Pediatrics (AAP) phototherapy nomogram that incorporates age in hours and risk factors (including G6PD deficiency) to decide on treatment thresholds.

Treatment Options

Treatment aims to lower serum bilirubin safely and prevent hemolysis.

Phototherapy

• Conventional blue‑light phototherapy: Median wavelength 460 nm; accelerates conversion of bilirubin to water‑soluble isomers.
• Intensive (high‑intensity) phototherapy: Used when TB exceeds the high‑risk threshold.
• Fiber‑optic or LED devices: Offer better skin coverage and lower heat exposure.

Exchange Transfusion

Reserved for bilirubin levels that approach or exceed the exchange‑transfusion threshold (≈ 30 mg/dL in term infants) or when rapid clinical deterioration occurs despite maximal phototherapy.

Intravenous Immunoglobulin (IVIG)

May be considered when hemolysis is driven by maternal antibodies (e.g., ABO incompatibility) in addition to G6PD deficiency, as it blocks Fc‑mediated red‑cell destruction.

Supportive Measures

• Ensuring adequate feeding: Breastfeeding every 2–3 hours promotes stooling and bilirubin excretion.
• Hydration: Maintain urine output >1 mL/kg/h.
• Temperature control: Keep the infant warm but avoid overheating, which can increase bilirubin production.

Lifestyle & Medication Precautions

• Avoid drugs known to precipitate hemolysis (e.g., sulfonamides, primaquine, dapsone).
• Do not give fava beans or related legumes to the infant or breastfeeding mother.
• Consult a pharmacist or pediatrician before starting any new medication.

Living with G6PD‑Related Neonatal Jaundice

After the acute episode resolves, families often wonder how to manage the condition long‑term.

Home‑Monitoring Tips

• Track feeding frequency: Aim for at least 8–12 feeds per day.
• Observe stool and urine color: Dark stools or reduced urine may signal ongoing bilirubin elevation.
• Watch the skin and eyes: Any re‑appearance of yellowing warrants a pediatric check.
• Maintain a jaundice diary: Record feeding times, weight changes, and bilirubin readings if taken at home.

Family Education

• Provide a written list of **contraindicated medications** and foods.
• Inform caregivers about the hereditary nature of G6PD deficiency and encourage testing of siblings and future children.
• Encourage routine pediatric visits; most infants will have a follow‑up bilirubin check at 48–72 hours of life.

Vaccinations

Standard immunization schedules are safe. There is no evidence that vaccines trigger hemolysis in G6PD‑deficient infants (CDC, 2020).

Prevention

Because the enzyme deficiency itself cannot be “cured,” prevention focuses on reducing hemolytic triggers and early detection of jaundice.

• Newborn screening: Many countries include G6PD testing in routine heel‑stick panels. Ensure the test is performed before hospital discharge.
• Early bilirubin assessment: Obtain a serum TB level before 24 hours in high‑risk infants (e.g., male, Asian, African descent, family history).
• Breastfeeding support: Prompt lactation assistance helps achieve adequate milk transfer, decreasing bilirubin re‑absorption.
• Avoid oxidative substances: Educate mothers about avoiding fava beans, certain herbal teas, and over‑the‑counter medications that may pass into breast milk.

Complications

If jaundice is not treated promptly, excess unconjugated bilirubin can cross the blood‑brain barrier, leading to serious outcomes.

• Kernicterus (bilirubin‑induced neurologic dysfunction): Permanent motor deficits, auditory neuropathy, gaze palsy, and intellectual disability.
• Acute bilirubin encephalopathy: Reversible stages of lethargy, hypotonia, and seizures if treated early.
• Severe hemolytic anemia: May require transfusion and can exacerbate jaundice.
• Chronic liver dysfunction: Rare, but prolonged hyperbilirubinemia can strain hepatic function.

When to Seek Emergency Care

References

• World Health Organization. G6PD Deficiency: A Global Prevalence Study. 2021.
• Centers for Disease Control and Prevention. Glucose‑6‑Phosphate Dehydrogenase Deficiency. Updated 2023. https://www.cdc.gov/ncbddd/hemoglobinopathies/g6pd.html
• American Academy of Pediatrics. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;149(4):e2022055035.
• Mayo Clinic. Neonatal Jaundice. Accessed May 2026. https://www.mayoclinic.org
• Cleveland Clinic. G6PD Deficiency. 2024. https://my.clevelandclinic.org
• NIH National Institute of Diabetes and Digestive and Kidney Diseases. Neonatal Hyperbilirubinemia. 2023.

```